<p>Agios 制药（NASDAQ:AGIO - 获取免费报告）在周四发布的一份报告中，将其目标价格从 62.00 美元上调至 65.00 美元，HC Wainwright 报道。该券商目前对这家生物制药公司的股票给予 “买入” 评级。HC Wainwright 的目标价格意味着与该公司之前收盘价相比，潜在上涨幅度为 129.02%。</p>
<p>获取 <strong>Agios 制药</strong> 的提醒：</p>
<p>其他一些股票研究分析师也最近对 AGIO 发表了评论。高盛集团在 11 月 20 日的研究报告中将 Agios 制药的股票目标价格从 40.00 美元下调至 25.00 美元，并对该股票给予 “中性” 评级。Leerink Partners 在 12 月 26 日的报告中将 Agios 制药的股票目标价格从 34.00 美元上调至 40.00 美元，并给予该股票 “跑赢大盘” 评级。摩根大通在 1 月 6 日的研究报告中将 Agios 制药的股票目标价格从 20.00 美元上调至 25.00 美元，并给予该股票 “中性” 评级。美国银行在 12 月 24 日的研究报告中将 Agios 制药的目标价格从 32.00 美元上调至 34.00 美元，并给予该公司 “买入” 评级。最后，Truist Financial 在 12 月 24 日的报告中将 Agios 制药的目标价格从 32.00 美元上调至 38.00 美元，并给予该股票 “买入” 评级。六位股票研究分析师对该股票给予 “买入” 评级，四位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价格为 39.78 美元。</p>
<p><strong>获取我们对 Agios 制药的最新股票分析</strong></p>
<h2>Agios 制药股票上涨 2.4%</h2>
<p>NASDAQ:AGIO 的股票在周四交易中上涨 0.67 美元，达到 28.38 美元。该股票的交易量为 471,346 股，而其平均交易量为 925,984 股。Agios 制药的 12 个月低点为 22.24 美元，12 个月高点为 46.00 美元。该股票的 50 日简单移动平均线为 27.37 美元，200 日简单移动平均线为 34.17 美元。该股票的市值为 16.5 亿美元，市盈率为-4.05，贝塔值为 0.91。</p>
<p>Agios 制药（NASDAQ:AGIO - 获取免费报告）最近于 2 月 12 日发布了季度财报。这家生物制药公司报告本季度每股收益为（1.85 美元），超出市场共识预期的（1.96 美元）0.11 美元。该季度的营业收入为 1997 万美元，而市场共识预期为 1206 万美元。Agios 制药的净利润率为-895.86%，股本回报率为-28.35%。该公司的季度收入同比增长 86.9%。整体来看，卖方分析师预测 Agios 制药在当前年度的每股收益将为-6.85 美元。</p>
<h2>内部买卖</h2>
<p>在其他新闻中，内部人士 Sarah Gheuens 于 12 月 30 日出售了 2932 股该公司的股票。股票以平均价格 27.09 美元出售，总价值为 79427.88 美元。交易完成后，该内部人士直接持有 64895 股公司股票，价值约为 1755296.55 美元。此交易代表其持股比例减少了 4.33%。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，内部人士 James William Burns 于 12 月 30 日出售了 2932 股该公司的股票。股票以平均价格 27.09 美元出售，总交易额为 79427.88 美元。交易完成后，该内部人士直接持有 31718 股公司股票，价值 859240.62 美元。此交易代表其持股比例减少了 8.46%。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士共出售了价值 901977 美元的 33303 股公司股票。公司内部人士持有公司股票的 4.30%。</p>
<h2>Agios 制药的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近修改了对该股票的持有。AlphaCentric Advisors LLC 在第四季度购买了 Agios 制药的新头寸，价值 358,000 美元。纽约州共同退休基金在第四季度将其在 Agios 制药的股份增加了 3.9%。纽约州共同退休基金现在持有 51707 股生物制药公司的股票，价值 1407000 美元，此前在该期间内又购买了 1917 股。Campbell &amp; CO 投资顾问 LLC 在第四季度购买了 Agios 制药的新股份，价值约 224,000 美元。Knott David M Jr 在第四季度获得了 Agios 制药的新头寸，价值约 490,000 美元。最后，Alps Advisors Inc.在第四季度将其在 Agios 制药的持股增加了 73.8%。Alps Advisors Inc.现在持有 47881 股生物制药公司的股票，价值 1303000 美元，此前在上个季度又购买了 20327 股。</p>
<h2>关于 Agios 制药</h2>
<p>（获取免费报告）</p>
<p>Agios 制药公司成立于 2008 年，是从 Dana-Farber 癌症研究所和 Broad Institute 的研究中分拆出来的生物制药公司。总部位于马萨诸塞州剑桥，Agios 专注于理解和针对细胞代谢，以开发用于癌症和罕见遗传疾病的新疗法。该公司的科学平台整合了基因组发现、代谢分析和精准医学方法，以识别和推进能够纠正或利用代谢功能障碍的小分子候选药物。</p>
<p>Agios 的主要产品是针对特定癌症突变的 IDH（异柠檬酸脱氢酶）抑制剂。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Agios Pharmaceuticals</li>
<li>USAU：投资者无法忽视的美国黄金 - 铜故事。</li>
<li>国防部刚刚获得了一家新的无人机供应商</li>
<li>认为你错过了白银？你错了。原因在这里。</li>
<li>何时购买黄金（从数学角度）</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Agios Pharmaceuticals 吗？</h2>
<p>在你考虑 Agios Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Agios Pharmaceuticals 并不在名单上。</p>
<p>虽然 Agios Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Agios制药

<p>HC Wainwright 将 Agios Pharmaceuticals (NASDAQ:AGIO) 的目标价格从 62.00 美元上调至 65.00 美元，维持 “买入” 评级。这个新目标暗示相较于前一交易日收盘价有 129.02% 的潜在上涨空间。其他分析师的看法各异，高盛将其目标下调至 25.00 美元，并维持 “中性” 评级，而其他分析师则设定了更高的目标。Agios 的股价上涨 2.4%，至 28.38 美元，市值为 16.5 亿美元。该公司报告的季度每股收益为（1.85 美元），超出预期，收入为 1997 万美元，同比增长 86.9%</p>

<p>Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) had its price objective hoisted by HC Wainwright from $62.00 to $65.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a &#34;buy&#34; rating on the biopharmaceutical company's stock. HC Wainwright's price objective would indicate a potential upside of 129.02% from the company's previous close.</p>
<div class="lb-trans"><p>Agios 制药（NASDAQ:AGIO - 获取免费报告）在周四发布的一份报告中，将其目标价格从 62.00 美元上调至 65.00 美元，HC Wainwright 报道。该券商目前对这家生物制药公司的股票给予 “买入” 评级。HC Wainwright 的目标价格意味着与该公司之前收盘价相比，潜在上涨幅度为 129.02%。</p>
</div><p>Get <strong>Agios Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Agios 制药</strong> 的提醒：</p>
</div><p>A number of other equities research analysts have also recently commented on AGIO. The Goldman Sachs Group dropped their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a &#34;neutral&#34; rating on the stock in a research note on Thursday, November 20th. Leerink Partners increased their price target on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, December 26th. JPMorgan Chase &amp; Co. upped their price objective on shares of Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, January 6th. Bank of America raised their target price on Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, December 24th. Finally, Truist Financial upped their price target on Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, December 24th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of &#34;Hold&#34; and an average price target of $39.78.</p>
<div class="lb-trans"><p>其他一些股票研究分析师也最近对 AGIO 发表了评论。高盛集团在 11 月 20 日的研究报告中将 Agios 制药的股票目标价格从 40.00 美元下调至 25.00 美元，并对该股票给予 “中性” 评级。Leerink Partners 在 12 月 26 日的报告中将 Agios 制药的股票目标价格从 34.00 美元上调至 40.00 美元，并给予该股票 “跑赢大盘” 评级。摩根大通在 1 月 6 日的研究报告中将 Agios 制药的股票目标价格从 20.00 美元上调至 25.00 美元，并给予该股票 “中性” 评级。美国银行在 12 月 24 日的研究报告中将 Agios 制药的目标价格从 32.00 美元上调至 34.00 美元，并给予该公司 “买入” 评级。最后，Truist Financial 在 12 月 24 日的报告中将 Agios 制药的目标价格从 32.00 美元上调至 38.00 美元，并给予该股票 “买入” 评级。六位股票研究分析师对该股票给予 “买入” 评级，四位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价格为 39.78 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Agios Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Agios 制药的最新股票分析</strong></p>
</div><h2>Agios Pharmaceuticals Stock Up 2.4%</h2>
<div class="lb-trans"><h2>Agios 制药股票上涨 2.4%</h2>
</div><p>Shares of NASDAQ:AGIO traded up $0.67 during trading on Thursday, hitting $28.38. The stock had a trading volume of 471,346 shares, compared to its average volume of 925,984. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $46.00. The stock has a 50-day simple moving average of $27.37 and a two-hundred day simple moving average of $34.17. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -4.05 and a beta of 0.91.</p>
<div class="lb-trans"><p>NASDAQ:AGIO 的股票在周四交易中上涨 0.67 美元，达到 28.38 美元。该股票的交易量为 471,346 股，而其平均交易量为 925,984 股。Agios 制药的 12 个月低点为 22.24 美元，12 个月高点为 46.00 美元。该股票的 50 日简单移动平均线为 27.37 美元，200 日简单移动平均线为 34.17 美元。该股票的市值为 16.5 亿美元，市盈率为-4.05，贝塔值为 0.91。</p>
</div><p>Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.85) EPS for the quarter, beating the consensus estimate of ($1.96) by $0.11. The business had revenue of $19.97 million for the quarter, compared to the consensus estimate of $12.06 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm's revenue for the quarter was up 86.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.</p>
<div class="lb-trans"><p>Agios 制药（NASDAQ:AGIO - 获取免费报告）最近于 2 月 12 日发布了季度财报。这家生物制药公司报告本季度每股收益为（1.85 美元），超出市场共识预期的（1.96 美元）0.11 美元。该季度的营业收入为 1997 万美元，而市场共识预期为 1206 万美元。Agios 制药的净利润率为-895.86%，股本回报率为-28.35%。该公司的季度收入同比增长 86.9%。整体来看，卖方分析师预测 Agios 制药在当前年度的每股收益将为-6.85 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, insider Sarah Gheuens sold 2,932 shares of the firm's stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the transaction, the insider directly owned 64,795 shares of the company's stock, valued at approximately $1,755,296.55. This trade represents a 4.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider James William Burns sold 2,932 shares of the firm's stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the insider directly owned 31,718 shares in the company, valued at $859,240.62. This trade represents a 8.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,303 shares of company stock worth $901,977 in the last ninety days. Company insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Sarah Gheuens 于 12 月 30 日出售了 2932 股该公司的股票。股票以平均价格 27.09 美元出售，总价值为 79427.88 美元。交易完成后，该内部人士直接持有 64895 股公司股票，价值约为 1755296.55 美元。此交易代表其持股比例减少了 4.33%。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，内部人士 James William Burns 于 12 月 30 日出售了 2932 股该公司的股票。股票以平均价格 27.09 美元出售，总交易额为 79427.88 美元。交易完成后，该内部人士直接持有 31718 股公司股票，价值 859240.62 美元。此交易代表其持股比例减少了 8.46%。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士共出售了价值 901977 美元的 33303 股公司股票。公司内部人士持有公司股票的 4.30%。</p>
</div><h2>Institutional Trading of Agios Pharmaceuticals</h2>
<div class="lb-trans"><h2>Agios 制药的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of the stock. AlphaCentric Advisors LLC purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter worth $358,000. New York State Common Retirement Fund raised its stake in Agios Pharmaceuticals by 3.9% during the fourth quarter. New York State Common Retirement Fund now owns 51,707 shares of the biopharmaceutical company's stock worth $1,407,000 after purchasing an additional 1,917 shares during the period. Campbell &amp; CO Investment Adviser LLC purchased a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at approximately $224,000. Knott David M Jr acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $490,000. Finally, Alps Advisors Inc. lifted its holdings in Agios Pharmaceuticals by 73.8% in the fourth quarter. Alps Advisors Inc. now owns 47,881 shares of the biopharmaceutical company's stock valued at $1,303,000 after acquiring an additional 20,327 shares during the last quarter.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近修改了对该股票的持有。AlphaCentric Advisors LLC 在第四季度购买了 Agios 制药的新头寸，价值 358,000 美元。纽约州共同退休基金在第四季度将其在 Agios 制药的股份增加了 3.9%。纽约州共同退休基金现在持有 51707 股生物制药公司的股票，价值 1407000 美元，此前在该期间内又购买了 1917 股。Campbell &amp; CO 投资顾问 LLC 在第四季度购买了 Agios 制药的新股份，价值约 224,000 美元。Knott David M Jr 在第四季度获得了 Agios 制药的新头寸，价值约 490,000 美元。最后，Alps Advisors Inc.在第四季度将其在 Agios 制药的持股增加了 73.8%。Alps Advisors Inc.现在持有 47881 股生物制药公司的股票，价值 1303000 美元，此前在上个季度又购买了 20327 股。</p>
</div><h2>About Agios Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Agios 制药</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.</p>
<div class="lb-trans"><p>Agios 制药公司成立于 2008 年，是从 Dana-Farber 癌症研究所和 Broad Institute 的研究中分拆出来的生物制药公司。总部位于马萨诸塞州剑桥，Agios 专注于理解和针对细胞代谢，以开发用于癌症和罕见遗传疾病的新疗法。该公司的科学平台整合了基因组发现、代谢分析和精准医学方法，以识别和推进能够纠正或利用代谢功能障碍的小分子候选药物。</p>
</div><p>Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.</p>
<div class="lb-trans"><p>Agios 的主要产品是针对特定癌症突变的 IDH（异柠檬酸脱氢酶）抑制剂。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Agios Pharmaceuticals</li>
<li>USAU: The U.S. Gold-Copper Story Investors Can’t Ignore.</li>
<li>The DoD just got a new drone supplier</li>
<li>Think You Missed Silver? You’re Wrong. Here’s Why.</li>
<li>When to buy gold (mathematically)</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Agios Pharmaceuticals</li>
<li>USAU：投资者无法忽视的美国黄金 - 铜故事。</li>
<li>国防部刚刚获得了一家新的无人机供应商</li>
<li>认为你错过了白银？你错了。原因在这里。</li>
<li>何时购买黄金（从数学角度）</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=AGIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Agios Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Agios Pharmaceuticals 吗？</h2>
</div><p>Before you consider Agios Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Agios Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Agios Pharmaceuticals 并不在名单上。</p>
</div><p>While Agios Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Agios Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 对 Agios 制药（NASDAQ:AGIO）的股票价格发布了积极的预测